These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8737061)

  • 1. Surprising pharmacological activity of analogues designed by substitution of position 3 in arginine vasopressin (AVP) and 8-D-arginine vasopressin with L-2-napthylalanine.
    Lammek B; Konieczna E; Trzeciak HI; Kozłowski A; Szymkowiak J; Stojko R; Kupryszewski G
    J Pharm Pharmacol; 1996 Mar; 48(3):316-9. PubMed ID: 8737061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of L-naphthylalanine in position 3 of AVP and its analogues on their pharmacological properties.
    Lammek B; Czaja M; Derdowska I; Rekowski P; Trzeciak HI; Sikora P; Szkróbka W; Stojko R; Kupryszewski G
    J Pept Res; 1997 Mar; 49(3):261-8. PubMed ID: 9151259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly potent 1-aminocyclohexane-1-carboxylic acid substituted V2 agonists of arginine vasopressin.
    Kowalczyk W; Prahl A; Derdowska I; Dawidowska O; Slaninová J; Lammek B
    J Med Chem; 2004 Nov; 47(24):6020-4. PubMed ID: 15537356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments.
    Lammek B; Czaja M; Derdowska I; Lempicka E; Sikora P; Szkróbka W; Trzeciak HI
    J Pept Res; 1998 Feb; 51(2):149-54. PubMed ID: 9516050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.
    Kwiatkowska A; Sobolewski D; Prahl A; Borovicková L; Slaninová J; Lammek B
    Eur J Med Chem; 2009 Jul; 44(7):2862-67. PubMed ID: 19418631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
    Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetyl-[2-(O-methyl)tyrosine]arginine-vasopressin, an interesting antagonist of the vasopressor response to vasopressin.
    Jones DA; Sawyer WH
    J Med Chem; 1980 Jun; 23(6):696-8. PubMed ID: 7392038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
    Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
    J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and some pharmacological properties of 18 potent O-alkyltyrosine-substituted antagonists of the vasopressor responses to arginine-vasopressin.
    Manning M; Lammek B; Bankowski K; Seto J; Sawyer WH
    J Med Chem; 1985 Oct; 28(10):1485-91. PubMed ID: 4045923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analogues of arginine vasopressin modified in position 2 or 3 with naphthylalanine: selective antagonists of oxytocin in-vitro.
    Sobocińska M; Lempicka E; Konieczna E; Derdowska I; Lammek B; Melhem S; Kozik W; Janecka J; Janecki M; Trzeciak HI
    J Pharm Pharmacol; 2000 Sep; 52(9):1105-12. PubMed ID: 11045891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of N-terminal part modification of arginine vasopressin analogues with 2-aminoindane-2-carboxylic acid: a highly potent V2 agonist.
    Kowalczyk W; Sobolewski D; Prahl A; Derdowska I; Borovicková L; Slaninová J; Lammek B
    J Med Chem; 2007 Jun; 50(12):2926-9. PubMed ID: 17500550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
    Manning M; Stoev S; Kolodziejczyk A; Klis WA; Kruszynski M; Misicka A; Olma A; Wo NC; Sawyer WH
    J Med Chem; 1990 Nov; 33(11):3079-86. PubMed ID: 2231609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analogs of arginine vasopressin modified in position 3 with (R)-alpha-hydroxymethylphenylalanine.
    Lempicka E; Slaninova J; Olma A; Lammek B
    J Pept Res; 1999 May; 53(5):554-9. PubMed ID: 10424351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vasopressin on the human non-pregnant uterus: studies with analogues of different vasopressor potencies.
    Melin P; Trojnar J; Carlsson AM; Bengtsson B; Akerlund M; Robinson I
    Eur J Pharmacol; 1988 Mar; 148(1):93-9. PubMed ID: 3383999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-pentamethylenepropionic acid),2-D-isoleucine,4- valine]arginine-vasopressin at position 4.
    Manning M; Nawrocka E; Misicka A; Olma A; Klis WA; Seto J; Sawyer WH
    J Med Chem; 1984 Apr; 27(4):423-9. PubMed ID: 6708045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and some pharmacologic properties of five novel V1 or V1/V2 antagonists of AVP.
    Lammek B; Wang YX; Derdowska I; Franco R; Gavras H
    Peptides; 1989; 10(5):1109-12. PubMed ID: 2608555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.